tetano
Editor, Senior Moderator
Eur J Med Chem
. 2023 Aug 28;260:115772.
doi: 10.1016/j.ejmech.2023.115772. Online ahead of print. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li[SUP] 1 [/SUP], Yongcheng Song[SUP] 2 [/SUP]
Affiliations
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003 infected ∼8000 people in 26 countries with 800 deaths, which was soon contained and eradicated by syndromic surveillance and enhanced quarantine. A closely related coronavirus SARS-CoV-2, the causative agent of COVID-19 identified in 2019, has been dramatically more contagious and catastrophic. It has infected and caused various flu-like symptoms of billions of people in >200 countries, including >6 million people died of or with the virus. Despite the availability of several vaccines and antiviral drugs against SARS-CoV-2, finding new therapeutics is needed because of viral evolution and a possible emerging coronavirus in the future. The main protease (M[SUP]pro[/SUP]) of these coronaviruses plays important roles in their life cycle and is essential for the viral replication. This article represents a comprehensive review of the function, structure and inhibition of SARS-CoV and -CoV-2 M[SUP]pro[/SUP], including structure-activity relationships, protein-inhibitor interactions and clinical trial status.
Keywords: Drug discovery; Main protease; SARS-CoV-2; Small-molecule inhibitor
. 2023 Aug 28;260:115772.
doi: 10.1016/j.ejmech.2023.115772. Online ahead of print. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li[SUP] 1 [/SUP], Yongcheng Song[SUP] 2 [/SUP]
Affiliations
- PMID: 37659195
- DOI: 10.1016/j.ejmech.2023.115772
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003 infected ∼8000 people in 26 countries with 800 deaths, which was soon contained and eradicated by syndromic surveillance and enhanced quarantine. A closely related coronavirus SARS-CoV-2, the causative agent of COVID-19 identified in 2019, has been dramatically more contagious and catastrophic. It has infected and caused various flu-like symptoms of billions of people in >200 countries, including >6 million people died of or with the virus. Despite the availability of several vaccines and antiviral drugs against SARS-CoV-2, finding new therapeutics is needed because of viral evolution and a possible emerging coronavirus in the future. The main protease (M[SUP]pro[/SUP]) of these coronaviruses plays important roles in their life cycle and is essential for the viral replication. This article represents a comprehensive review of the function, structure and inhibition of SARS-CoV and -CoV-2 M[SUP]pro[/SUP], including structure-activity relationships, protein-inhibitor interactions and clinical trial status.
Keywords: Drug discovery; Main protease; SARS-CoV-2; Small-molecule inhibitor